A Phase 3 interventional study of NVA237 50 µg and indacaterol 150 µg and Placebo to NVA237 and indacaterol 150 µg in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals. Completed at 80 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-11-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 23rd largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 25th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 449 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 39th largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 59 in phase 3, and was the 69th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: NVA237 50 µg and indacaterol 150 µg
Drug: Placebo to NVA237 and indacaterol 150 µg
Drug page: Glycopyrrolate
NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
Also known as: Glycopyrronium Bromide
Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
Trough Forced Expiratory Volume at 1 Second (FEV1)
Centralized spirometry according to internationally accepted standards was used. The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect. If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward. These measurements had to have been taken before the next dose of study medication. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
Time frame: 12 weeks
FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose
Centralized spirometry was used according to internationally accepted standards was used. The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time. Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated). Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
Time frame: 12 weeks
Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks
Centralized spirometry was used according to internationally accepted standards was used. Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect. If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
Time frame: 12 weeks
FEV1 at Individual Time-points
Centralized spirometry according to internationally accepted standards was used. FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
Time frame: Day 1, Day 29, Day 57 and Days 84/85
Forced Vital Capacity (FVC) at Individual Time-points
FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.
Time frame: Day 1, Day 29, Day 57 and Days 84/85
Inspiratory Capacity (IC) at Individual Time-points
Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.
Time frame: Day 1, Days 84/85
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening. The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.
Time frame: Baseline, 12 weeks
Transitional Dyspnea Index (TDI) Focal Score
Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI). Analysis was done via mixed model. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort. BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity. TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration. A TDI focal score of 1 is considered a minimal clinically important difference.
Time frame: baseline, 12 weeks
Change From Baseline in Mean Daily Total and Individual Symptom Scores
The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied. For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom. The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).
Time frame: Baseline, 12 weeks
Number of Participants With Adverse Events and Serious Adverse Events
All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.
Time frame: 12 weeks
The number of patients randomized was 449. Of these participants, the Full Analysis Set (FAS) comprised 446 participants who received at least one dose of study drug and had no major deviations which led to removal from the FAS. The Safety Set included 447 participants who received at least one dose of study drug.
| Milestone | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Started | 226 | 223 |
| Safety set | 226 | 221 |
| Full analysis set | 226 | 220 |
| Completed | 212 | 210 |
| Not completed | 14 | 13 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Administrative problems | 2 | 1 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Protocol deviation | 5 | 3 |
Centralized spirometry according to internationally accepted standards was used. The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect. If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward. These measurements had to have been taken before the next dose of study medication. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
| Liters | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Trough Forced Expiratory Volume at 1 Second (FEV1) | 1.499 ± 0.0135 | 1.436 ± 0.0136 |
Centralized spirometry was used according to internationally accepted standards was used. The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time. Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated). Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
| Liters | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose | 1.641 ± 0.0132 | 1.530 ± 0.0134 |
Centralized spirometry was used according to internationally accepted standards was used. Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect. If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
| Liters | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks | 1.702 ± 0.0137 | 1.596 ± 0.0138 |
Centralized spirometry according to internationally accepted standards was used. FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
| Liters | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Day 1, 30 minutes (min) post dose (n=208,199) | 1.544 ± 0.0086 | 1.467 ± 0.0088 |
| Day 1, 1 hour (h) post dose (n=214,209) | 1.589 ± 0.0102 | 1.479 ± 0.0104 |
| Day 1, 2 h post dose (n=212,207) | 1.626 ± 0.0114 | 1.506 ± 0.0117 |
| Day 1, 4 h post dose (n=206,213) | 1.630 ± 0.0122 | 1.518 ± 0.0122 |
| Day 1, 23 h 15 min post dose (n=201,203) | 1.481 ± 0.0118 | 1.409 ± 0.0118 |
| Day 1, 23 h 45 min post dose (n=213,204) | 1.502 ± 0.0109 | 1.425 ± 0.0112 |
| Day 29, 45 min pre-dose (n=198,202) | 1.491 ± 0.0150 | 1.438 ± 0.0150 |
| Day 29, 15 min pre-dose (n=198,200) | 1.524 ± 0.0156 | 1.470 ± 0.0155 |
| Day 29, 30 min post dose (n=202,201) | 1.617 ± 0.0152 | 1.508 ± 0.0154 |
| Day 29, 1 h post dose (n=200,199) | 1.648 ± 0.0144 | 1.524 ± 0.0145 |
| Day 56, 45 min pre-dose (n=201,202) | 1.482 ± 0.0145 | 1.418 ± 0.0146 |
| Day 56, 15 min pre-dose (n=199,198) | 1.509 ± 0.0148 | 1.443 ± 0.0149 |
| Day 56, 30 min post dose (n=200,200) | 1.606 ± 0.0144 | 1.495 ± 0.0146 |
| Day 56, 1 h post dose (n=197,204) | 1.634 ± 0.0149 | 1.520 ± 0.0148 |
| Days 84/85, 45 min pre-dose (n=201,206) | 1.459 ± 0.0127 | 1.411 ± 0.0126 |
| Days 84/85, 15 min pre-dose (n=190,196) | 1.476 ± 0.0129 | 1.439 ± 0.0129 |
| Days 84/85, 30 min post dose (n=198,199) | 1.604 ± 0.0125 | 1.514 ± 0.0126 |
| Days 84/85, 1 h post dose (n=201,200) | 1.638 ± 0.0125 | 1.514 ± 0.0126 |
| Days 84/85, 2 h post dose (n=198,201) | 1.665 ± 0.0139 | 1.542 ± 0.0139 |
| Days 84/85, 4 h post dose (n=200,198) | 1.620 ± 0.0162 | 1.529 ± 0.0165 |
| Days 84/85, 23 h 15 min post dose (n=193,188) | 1.474 ± 0.0139 | 1.426 ± 0.0143 |
| Days 84/85, 23 h 45 min post dose (n=197,199) | 1.508 ± 0.0147 | 1.452 ± 0.0148 |
FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.
| Liters | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Day 1, 30 min post dose (n=208,199) | 3.214 ± 0.0181 | 3.135 ± 0.0186 |
| Day 1, 1 h post dose (n=214,209) | 3.295 ± 0.0260 | 3.182 ± 0.0264 |
| Day 1, 2 h post dose (n=212,207) | 3.325 ± 0.0229 | 3.200 ± 0.0234 |
| Day 1, 4 h post dose (n=206,213) | 3.340 ± 0.0239 | 3.218 ± 0.0238 |
| Day 1, 23 h 15 min post dose (n=201,203) | 3.155 ± 0.0267 | 3.039 ± 0.0268 |
| Day 1, 23 h 45 min post dose (n=213,204) | 3.201 ± 0.0257 | 3.095 ± 0.0263 |
| Day 29, 45 min pre-dose (n=198,202) | 3.146 ± 0.0299 | 3.043 ± 0.0299 |
| Day 29, 15 min pre-dose (n=198,200) | 3.184 ± 0.0315 | 3.092 ± 0.0314 |
| Day 29, 30 min post dose (n=202,201) | 3.316 ± 0.0338 | 3.201 ± 0.0341 |
| Day 29, 1 h post dose (n=200,199) | 3.362 ± 0.0336 | 3.197 ± 0.0337 |
| Day 56, 45 min pre-dose (n=201,202) | 3.102 ± 0.0302 | 3.015 ± 0.0303 |
| Day 56, 15 min pre-dose (n=199,198) | 3.156 ± 0.0321 | 3.086 ± 0.0322 |
| Day 56, 30 min post dose (n=200,200) | 3.282 ± 0.0316 | 3.190 ± 0.0319 |
| Day 56, 1 h post dose (n=197,204) | 3.327 ± 0.0323 | 3.219 ± 0.0321 |
| Days 84/85, 45 min pre-dose (n=201,206) | 3.052 ± 0.0280 | 3.016 ± 0.0279 |
| Days 84/85, 15 min pre-dose (n=190,196) | 3.064 ± 0.0256 | 3.012 ± 0.0254 |
| Days 84/85, 30 min post dose (n=198,199) | 3.246 ± 0.0262 | 3.162 ± 0.0264 |
| Days 84/85, 1 h post dose (n=201,200) | 3.312 ± 0.0291 | 3.179 ± 0.0294 |
| Days 84/85, 2 h post dose (n=198,201) | 3.318 ± 0.0261 | 3.181 ± 0.0261 |
| Days 84/85, 4 h post dose (n=200,198) | 3.251 ± 0.0292 | 3.161 ± 0.0297 |
| Days 84/85, 23 h 15 min post dose (n=193,188) | 3.123 ± 0.0285 | 3.050 ± 0.0292 |
| Days 84/85, 23 h 45 min post dose (n=197,199) | 3.136 ± 0.0256 | 3.047 ± 0.0258 |
Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.
| Liters | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Day 1, 25 min post dose (n=164,168) | 2.493 ± 0.0234 | 2.434 ± 0.0231 |
| Day 1, 1 h 55 min (n=161,176) | 2.587 ± 0.0294 | 2.478 ± 0.0287 |
| Day 1, 3 h 55 min (n=160,173) | 2.557 ± 0.0298 | 2.475 ± 0.0291 |
| Days 84/85, 20 min pre-dose (n=144,148) | 2.444 ± 0.0327 | 2.363 ± 0.0324 |
| Days 84/85, 25 min post dose (n=149,145) | 2.580 ± 0.0372 | 2.420 ± 0.0377 |
| Days 84/85, 1 h 55 min post dose (n=146,153) | 2.607 ± 0.0388 | 2.485 ± 0.0384 |
| Days 84/85, 3 h 55 min (n=146,145) | 2.577 ± 0.0332 | 2.439 ± 0.0333 |
| Days 84/85, 23 h 40 min (n=153,150) | 2.405 ± 0.0371 | 2.337 ± 0.0376 |
The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening. The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.
| Number of puffs | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Change From Baseline in Mean Daily Number of Puffs of Rescue Medication | -1.9 ± 0.16 | -1.8 ± 0.16 |
Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI). Analysis was done via mixed model. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort. BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity. TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration. A TDI focal score of 1 is considered a minimal clinically important difference.
| Score | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Transitional Dyspnea Index (TDI) Focal Score | 2.506 ± 0.2781 | 2.012 ± 0.2797 |
The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied. For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom. The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).
| Score | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Total symptom score | -1.2 ± 0.13 | -1.1 ± 0.13 |
| Respiratory symptom score | -0.3 ± 0.03 | -0.2 ± 0.03 |
| Cough symptom score | -0.2 ± 0.03 | -0.2 ± 0.03 |
| Wheeze symptom score | -0.3 ± 0.03 | -0.2 ± 0.03 |
| Sputum production score | -0.1 ± 0.03 | -0.1 ± 0.03 |
| Sputum color score | -0.1 ± 0.02 | -0.1 ± 0.02 |
| Breathless symptom score | -0.2 ± 0.03 | -0.2 ± 0.03 |
| Sore throat symptom score | 0.0 ± 0.01 | 0.0 ± 0.01 |
| Cold symptom score | 0.0 ± 0.02 | 0.0 ± 0.02 |
| Fever symptom score | 0.0 ± 0.01 | 0.0 ± 0.01 |
All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.
| Number of participants | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Adverse Events (serious and non-serious) | 85 | 75 |
| Serious adverse events | 5 | 5 |
| Deaths | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 + Indacaterol | — | 5/226 (2.2%) | 32/226 (14.2%) |
| Placebo to NVA237 + Indacaterol | — | 5/221 (2.3%) | 27/221 (12.2%) |
| Event | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/226 | 2/221 |
| Angina pectorisCardiac disorders | 0/226 | 1/221 |
| Urinary tract infectionInfections and infestations | 0/226 | 1/221 |
| Rib fractureInjury, poisoning and procedural complications | 0/226 | 1/221 |
| Renal failure acuteRenal and urinary disorders | 0/226 | 1/221 |
| Inguinal herniaGastrointestinal disorders | 1/226 | 0/221 |
| HypersensitivityImmune system disorders | 1/226 | 0/221 |
| Bacterial infectionInfections and infestations | 1/226 | 0/221 |
| OsteitisMusculoskeletal and connective tissue disorders | 1/226 | 0/221 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/226 | 0/221 |
| Event | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 32/226 | 27/221 |
The baseline characteristics table was based on the safety set.
| Age, Continuous(Years) | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol | Total |
|---|---|---|---|
| Mean | 63.4 ± 8.44 | 64.1 ± 7.67 | 63.7 ± 8.07 |
| Sex: Female, Male(Participants) | NVA237 + Indacaterol | Placebo to NVA237 + Indacaterol | Total |
|---|---|---|---|
| Female | 46 | 35 | 81 |
| Male | 180 | 186 | 366 |
The record gives a start of May 2012, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →